Seegene Inc

Seegene CEO Jong-Yoon Chun receives medal of honor from Mongolian government

Sep 05, 2017

On September 4, 2017, Seegene CEO Jong-Yoon Chun received a medal of honor from Mongolia’s Ministry of Health and Welfare at the “Signing Ceremony for Project for Korea-Mongolia Anti-TB Collaboration in Ulaanbaatar” that was held at Holiday Inn Ulaanbaatar.

This government citation was an acknowledgement of Seegene’s leading role in the inter-governmental project to eliminate tuberculosis, which was launched in 2015 and is now in its third run this year. Chairman Jong-Kee Chun of the Seegene Medical Foundation and Chairman Young-Hak Yoo of the Chung Mong-Koo Foundation also received awards at the day’s event.

Since 2011, Seegene has participated in the STOP-TB partnership through various endeavors, such as a company-wide donation drive to accelerate the eradication of tuberculosis and participation in a tuberculosis testing program for the general public. Since 2015, the company has been working enthusiastically on the “Project for Korea-Mongolia Anti-TB Collaboration in Ulaanbaatar” in cooperation with the Korea National Tuberculosis Association and the Chung Mong-Koo Foundation.

In his acceptance speech, Seegene CEO Jong-Yoon Chun said, “Mongolia has a high tuberculosis prevalence rate, which makes early diagnosis of the disease more important than ever. To eradicate tuberculosis, we must step up our efforts by establishing a systematic basis for effective and timely treatment. I am deeply grateful for this citation and Seegene will continue its active participation in international projects that pursue the prompt eradication of tuberculosis worldwide.”

Seegene supplies Mongolia with molecular diagnostics equipment and reagents (AnyplexTMII MTB/MDR Detection) for accurate detection of tuberculosis and drug resistance using the latest in real-time PCR technology. Seegene’s molecular diagnostics product for tuberculosis is revolutionary, in that its enables testing to be completed within only six hours rather than the one month that was originally required. This product is now playing a key role in the effort to prevent and eradicate tuberculosis in Mongolia thanks to its ability to detect Mycobacterium tuberculosis and 25 mutations associated with multidrug-resistant tuberculosis through a single testing procedure.

The Project for Korea-Mongolia Anti-TB Collaboration in Ulaanbaatar is an international cooperative project that supports the local use of the latest models of medical test vehicles and testing equipment. The aim of the project is to conduct testing of Mongolians, who are vulnerable to tuberculosis, to discover potential tuberculosis patients in a timely and accurate manner and provide appropriate treatment. Through the project, over 17,000 Mongolian university students and socially vulnerable citizens have been tested for tuberculosis (as of August 2017). This resulted in the early discovery of over 110 tuberculosis patients, of whom 40 have been completely cured and have returned to society.